Advancements in genetic engineering最新文献_第7页

Genome Editing with ZFN, TALEN and CRISPR/Cas Systems:The Applications and Future Prospects ZFN、TALEN和CRISPR/Cas系统的基因组编辑:应用和未来展望

Advancements in genetic engineering Pub Date : 2014-02-01 DOI: 10.4172/2169-0111.1000E108

Youming Zhang

引用次数: 5

Advances in Genome Engineering Approaches 基因组工程方法的进展

Advancements in genetic engineering Pub Date : 2014-01-02 DOI: 10.4172/2169-0111.1000E107

A. Chhabra

{"title":"Advances in Genome Engineering Approaches","authors":"A. Chhabra","doi":"10.4172/2169-0111.1000E107","DOIUrl":"https://doi.org/10.4172/2169-0111.1000E107","url":null,"abstract":"Targeted genome editing is essential for functional characterization of a gene of interest. Targeted gene inactivation via homologous recombination made it feasible to create gene knockout animal models to ascertain the physiological role of the target genes; however, lower efficiency of site specific insertion of the genetically modified construct through homologous recombination has limited a wider applicability of this approach. Development of targeted gene knockdown through RNA interferce (RNAi) offered a cost effective, high-throughput alternative to homologous recombination, however, RNAi-mediated gene knockdown is incomplete, produces experiment to experiment variation, and could provide only a temporary inhibition of the gene function. Development of genome engineering methodologies utilizing nucleases linked to the guide sequences targeting a gene of interest, such as Zinc Finger Nucleases (ZFN), Transcription Activator like Effector Nucleases (TALEN) and Clustered Palindromic Repeats (CRISPR), are quite encouraging. A brief overview of recent advances in genome engineering approaches is provided with their respective advantages and limitations.","PeriodicalId":89733,"journal":{"name":"Advancements in genetic engineering","volume":"3 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2014-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2169-0111.1000E107","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70877093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The Potential Impact of Plant-made Biopharmaceuticals for the Improvement of Global Health 植物性生物制药对改善全球健康的潜在影响

Advancements in genetic engineering Pub Date : 2014-01-01 DOI: 10.4172/2169-0111.1000E106

K. Hefferon

引用次数: 0

Genetics Beyond Diabetes and Baldness 糖尿病和秃顶之外的遗传学

Advancements in genetic engineering Pub Date : 2014-01-01 DOI: 10.4172/2169-0111.1000E105

Z. Jaradat

{"title":"Genetics Beyond Diabetes and Baldness","authors":"Z. Jaradat","doi":"10.4172/2169-0111.1000E105","DOIUrl":"https://doi.org/10.4172/2169-0111.1000E105","url":null,"abstract":"Previously the concept of genetics was applied to a limited number of diseases with obvious phenotypes where simple people use to observe and relate. It was never easy to establish a clear cut of heritability range between genetic variation and a risk of suffering from a complex disorder due to many reasons including but not limited to; gene variations, non-linear interactions between genetic variance and phenotype severity, complex gene-gene interactions and many others [1]. However, every day, scientists in a research lab somewhere discover a genetic linkage to a disease or a syndrome. This has gone far beyond simple imagination where traits or syndromes used to be related almost exclusively to environment are now genetically linked. The difficulty of identification of patterns among the affected people and the involvement of multiple genes and environmental effects were all behind the difficulty in understanding the link of some of these syndromes/diseases or desired traits to genetics. Advances in genetics/ genomics and molecular biology have enabled geneticists to decipher some of the genes that are believed to be linked to some diseases. Recently genetic links has been established to many entities some of which were never thought of as linked with genetics while some were linked to genetics but with no understanding of their patterns. Obesity, neurological disorders, intelligence, asthma, cardiovascular diseases, periodontal diseases, longevity, deafness, cataracts, cancer are just few of the entities that are positively linked to genetics. This editorial will focus mainly on neuropsychiatric genetics including substance addiction, smoking and the genetics of anger.","PeriodicalId":89733,"journal":{"name":"Advancements in genetic engineering","volume":"3 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2169-0111.1000E105","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70877469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gene Therapy Gets its Momentum through the Marketing of an Engineered Virus to Treat Lipoprotein Lipase Deficiency 基因疗法通过一种治疗脂蛋白脂肪酶缺乏症的工程病毒的营销获得了动力

Advancements in genetic engineering Pub Date : 2013-11-28 DOI: 10.4172/2169-0111.1000E104

M. Conese

引用次数: 3

Legal Regulation of Genetically Modified Products in Azerbaijan 阿塞拜疆转基因产品的法律法规

Advancements in genetic engineering Pub Date : 2013-11-15 DOI: 10.4172/2169-0111.1000116

A. Mustafayeva, V. Mammadov, I. Ahmadov, L. Jafarova

引用次数: 1

The CRISPR-Cas9 System: A Powerful Tool for Genome Engineering and Regulation CRISPR-Cas9系统:基因组工程和调控的强大工具

Advancements in genetic engineering Pub Date : 2013-11-06 DOI: 10.4172/2169-0111.1000E103

Yongmin Yan, D. Wei

引用次数: 3

HLA-A24 is an unfavorable clinical prognostic factor in patients with stage III~IV (advanced) nasopharyngeal carcinoma HLA-A24是影响III~IV期(晚期)鼻咽癌患者临床预后的不利因素

Advancements in genetic engineering Pub Date : 2013-10-30 DOI: 10.4172/2169-0111.S1.002

Tian-wen He

{"title":"HLA-A24 is an unfavorable clinical prognostic factor in patients with stage III~IV (advanced) nasopharyngeal carcinoma","authors":"Tian-wen He","doi":"10.4172/2169-0111.S1.002","DOIUrl":"https://doi.org/10.4172/2169-0111.S1.002","url":null,"abstract":"Natural products, particularly polyketides are among the most important sources of antimicrobial compounds. 20% of the top selling drugs are polyketide based. In recent years genetic engineering has played a critical role in modifying biosynthetic pathways of different polyketide compounds as a way to create novel structures with improved clinical properties. Further investigation and understanding of these giant multi-enzyme complexes is necessary to achieve efficient synthetic engineering. \u0000 \u0000In many PKS systems including the mupirocin biosynthesis pathway, the thioesterase (TE) is normally considered as the end of the assembly line. However, expressing the CoA-ligase tmlU from the thiomarinol pathway in the mupirocin producer strain (Pseudomonas fluorescens NCIMB10586) revealed that TmlU could only release truncated pseudomonic acid when a TE domain was present. This finding led to the hypothesis that perhaps the TE domain could act as a tether for TmlU, in order for the latter to be able to capture the growing chain and perhaps load it onto the post TE pathway. This study also presents the first evidence of MmpB being involved in producing the 9-hydroxynonanoic acid in the mupirocin biosynthesis pathway.","PeriodicalId":89733,"journal":{"name":"Advancements in genetic engineering","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70877974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Recombinant immunotoxin as targeted therapeutic protein for cancer therapy 重组免疫毒素作为肿瘤治疗的靶向治疗蛋白

Advancements in genetic engineering Pub Date : 2013-10-30 DOI: 10.4172/2169-0111.S1.001

T. Bera

{"title":"Recombinant immunotoxin as targeted therapeutic protein for cancer therapy","authors":"T. Bera","doi":"10.4172/2169-0111.S1.001","DOIUrl":"https://doi.org/10.4172/2169-0111.S1.001","url":null,"abstract":"T therapy of cancer is getting more traction over the traditional chemotherapy to overcome the unavoidable side effects from the chemotherapeutic drugs. As scientists began to understand more about the molecular mechanism that distinguishes the cancer cells from its normal counterpart, they began to design new approach to attack the cancer cells more precisely. One of such successful approach is the development of monoclonal antibody against a cancer specific surface antigen that can be used as a delivery vehicle of toxic material selectively to the cancer cells. Our laboratory is involved in generating recombinant immunotoxin (RIT) as targeted therapeutic protein to treat cancer. Recombinant immunotoxins are chimeric proteins composed of the Fv portion of an antibody fused to a portion a lethal toxin. The immunotoxin binds to a surface antigen on a cancer cells, enters the cell by endocytosis where it inactivate the cellular machinery and eventually kills the cell. These proteins are expressed in E. coli, purified as clinical grade material and been tested in patients with various types of cancer in clinical trials. Modern molecular biological techniques were used to improve the efficacy of these agents in vitro and test them in the preclinical model system. Many immunotoxins have been tested in clinical trials but most success has been achieved in patients with hematologic tumors. Poor response against solid tumor for these agents is likely due to poor penetration into tumor masses as well as the neutralizing immune response to the toxin component of the immunotoxin. Studies are in progress in the laboratory to overcome those issues and eventually test them in clinical trials.","PeriodicalId":89733,"journal":{"name":"Advancements in genetic engineering","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2013-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70877842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Mouse artificial chromosome vectors for animal transgenesis 用于动物转基因的小鼠人工染色体载体

Advancements in genetic engineering Pub Date : 2013-10-30 DOI: 10.4172/2169-0111.S1.003

Y. Kazuki

引用次数: 0